Scientists Made Cancer Cells Look Like Bacteria So Immune Cells Would Eat Them

Cancer cells survive partly by persuading nearby immune cells to leave them alone. A new study tries to reverse that arrangement by giving tumour cells the molecular appearance of bacteria, encouraging macrophages to treat them as targets that should be swallowed.

KEY NUMBER
The share of macrophages engulfing cancer cells rose from about 20% in the control condition to roughly 70% after the cells received the bacteria-mimicking coating.

Why making cancer look infected could matter

Macrophages are immune cells that normally engulf microbes, damaged cells and cellular debris. Inside many solid tumours, however, chemical signals can push these cells toward an immunosuppressive state that protects the tumour rather than attacking it.

This is one reason solid cancers can resist immunotherapy. Existing immune treatments have transformed care for some patients, but the National Cancer Institute notes that cancers can hide from immune detection, switch immune cells off or reshape surrounding tissue to weaken the response.

The new strategy does not genetically engineer a patient’s macrophages outside the body. Instead, it attempts to recruit macrophages already inside a tumour and give them a familiar reason to attack.

How the bacterial disguise works

The researchers called their method bacteria-associated molecular pattern-induced recognition enhancement, or BAMPIRE. They extracted pathogen-associated molecular patterns from bacterial membranes, combined them with positively charged lipids and formed nanoparticles about 100 nanometres across.

Because cell membranes carry a negative electrical charge, the particles attached to the surface of cancer cells. The bacterial signals then activated several pattern-recognition receptors used by innate immune cells to detect infection.

In laboratory experiments, the coating stimulated inflammatory signalling and shifted tumour-associated macrophages toward a more active state. Macrophages engulfed the disguised cancer cells more frequently and processed tumour material that could potentially help engage the adaptive immune system.

What happened in mice

The researchers injected the particles directly into tumours in mice. Treatment slowed tumour growth, and the effect became stronger when combined with doxorubicin, a chemotherapy drug. Some mice experienced complete tumour regression, and similar overall trends appeared across three mouse cancer models.

Those results make the concept more substantial than a dish-only experiment. They still do not make it a cancer treatment. Mouse tumours, immune systems and controlled injections cannot reproduce the biological diversity, tumour size or previous treatments seen among human patients.

The study also raises an important delivery question. Positively charged particles can attach to cells through general electrostatic forces, not through a cancer-exclusive receptor. Local injection helped concentrate the material inside the target tumour, but reaching dispersed, deep or metastatic tumours would be more difficult.

What happens next

A convincing next stage would test the formulation in additional animal models that more closely reflect human tumours, while tracking where the particles travel and whether inflammation damages healthy organs. Researchers would also need to determine which cancers are accessible to local delivery and whether more selective targeting can reduce unwanted attachment.

If those questions can be answered, the approach could become a comparatively simple way to reawaken immune cells already present inside tumours and complement chemotherapy or other immunotherapies. For now, its real achievement is narrower but still intriguing: cancer cells were given a bacterial-looking surface, and the immune system’s professional eaters responded.